Belotero Volume Lidocaine 2x 1,0 ml

Belotero Volume Lidocaine delivers one of the most concentrated monophasic gels on the EU market—26 mg/mL cross-linked hyaluronic acid paired with 0.3 % lidocaine for analgesia.

Cohesive Polydensified Matrix (CPM®) technology disperses zones of high and low cross-link density inside the same syringe, giving the gel an elastic modulus that rivals bifasic volumisers while remaining supple enough for micro-adjustment. This architecture lets clinicians create deep bolus “pillars” over bone without the trampoline effect sometimes seen with stiffer competitors.

At 3 mg per millilitre, the lidocaine fraction strikes a balance between patient comfort and vasoconstrictive safety. Clinical audits of CPM-HA with lidocaine reported pain scores ≤2 out of 10 at injection and no increase in adverse events versus non-anaesthetised gels.

High HA weight means greater water affinity and lift per millilitre—ideal when skeletal resorption rather than dermal atrophy is the problem. In practice, most mid-face augmentations require 1.0–2.0 mL total, reducing product cost and needle passes. Because the polymer network is cohesive, ultrasound follow-up shows minimal migration even in dynamic zones. sample

Belotero Volume Lidocaine was engineered for sub-SMAS, deep-dermal or supraperiosteal placement to restore three-dimensional facial volume.

Best candidates include healthy adults with age- or weight-related flattening of the malar eminence, mandibular recession, or temple hollowing. MRI and photographic series confirm sustained cheek projection in both HIV-lipoatrophy and aesthetic cohorts. Thin-skinned patients tolerate the product well because CPM® minimises Tyndall risk.

Compared with CaHA and PLLA, Belotero Volume offers instant lift, reversibility with hyaluronidase and lower incidence of late nodules. Against other HA volumisers, the extra HA density yields approximately 15% higher G’ while requiring fewer cross-links, preserving moldability.

Practitioners report success in non-surgical chin augmentation and subtle brow support using micro-bolus technique; however, intranasal use is discouraged due to vascular risk. s

Each tamper-evident blister contains:
• 2 × 1 mL glass syringes pre-filled with sterile CPM-26 gel (Luer-Lock)
• 2 × 27 G ½″ needles & 2 × 30 G ½″ needles for linear threading or depot technique
• 2 × 27 G 37 mm blunt cannulas for periosteal fanning
• Multilingual IFU, peel-off batch stickers & UDI barcodes for full MDR Class III traceability
The unit is CE-marked and ISO 13485-certified; labels specify storage at 2–25 °C. Stress tests show <5 % viscosity shift after three freeze–thaw cycles, yet single-use policy applies once the sterile barrier is breached.[1]

Belotero Volume Lidocaine integrates quickly and, in MRI studies, retained 100% of injected volume at 12 months with no measurable HA loss. Real-world reviews echo 9–12 month longevity, tapering as individual hyaluronidase activity rises. The 26 mg/mL matrix binds up to 1,000-fold its weight in water, resisting compression and enzymatic cleavage longer than lower-concentration gels. CPM®’s variable cross-link pattern also slows diffusion of endogenous hyaluronidase, extending half-life. Most clinicians schedule an optional 0.5–1 mL touch-up at 9 months, aligning with the plateau of metabolic clearance seen on serial ultrasound. Retreatment sooner than 6 months seldom confers added benefit and may risk over-correction. A split-face randomized controlled trial comparing Belotero Volume to Juvederm Voluma showed equivalent volume at 18 months but softer palpation scores for Belotero.

Q1: Is Belotero Volume Lidocaine FDA-approved?
A1: Only its sibling Belotero Balance holds FDA clearance; Volume is CE-marked for use in Europe and many global markets.

Q2: How soon will I see results?
A2: Lift is immediate; minor oedema settles within 48 hours, revealing the final contour.

Q3: Can the filler be dissolved if I dislike the look?
A3: Yes—like all HA gels it responds to hyaluronidase, usually within minutes.

Belotero Volume Lidocaine is produced by Merz Aesthetics, a fourth-generation, family-owned German healthcare company founded in 1908 by chemist Friedrich Merz. Merz maintains ISO 13485-certified plants in Reinheim and Dessau, with batch-to-batch endotoxin limits stricter than the EU pharmacopeia. Sustainability is now a central pillar: the 2023 Merz Group CSR report pledges 42% CO₂ reduction and 100% renewable electricity for EU manufacturing by 2030. The firm also sponsors global women-in-STEM grants and reforestation projects through its MerzCares platform. Merz holds more than 200 patents, including the CPM® cross-linking method underpinning Belotero fillers. Independent reviews in Clinical, Cosmetic and Investigational Dermatology highlight the brand’s low granuloma rate and high patient satisfaction across ethnic skin types. In short, the company’s century-long dermatology heritage, rigorous quality systems and evolving green agenda position Belotero Volume Lidocaine as a clinically sound—and ethically conscious—choice for volume restoration.